2.00
12.99%
0.23
Pre-market:
2.11
0.11
+5.50%
Reviva Pharmaceuticals Holdings Inc stock is traded at $2.00, with a volume of 3.87M.
It is up +12.99% in the last 24 hours and up +49.25% over the past month.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
See More
Previous Close:
$1.77
Open:
$1.83
24h Volume:
3.87M
Relative Volume:
1.55
Market Cap:
$93.16M
Revenue:
-
Net Income/Loss:
$-37.65M
P/E Ratio:
-1.1976
EPS:
-1.67
Net Cash Flow:
$-24.14M
1W Performance:
+26.58%
1M Performance:
+49.25%
6M Performance:
+90.48%
1Y Performance:
-51.34%
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Name
Reviva Pharmaceuticals Holdings Inc
Sector
Industry
Phone
(408) 501-8881
Address
10080 N WOLFE ROAD, CUPERTINO
Compare RVPH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
2.00 | 93.16M | 0 | -37.65M | -24.14M | -1.67 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-20-23 | Initiated | ROTH MKM | Buy |
Jun-08-23 | Initiated | The Benchmark Company | Speculative Buy |
Jan-24-22 | Initiated | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News
Reviva Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals Unusual Options Activity - Benzinga
Traders Buy Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals' (RVPH) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 35.9% in December - MarketBeat
Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.25 - Defense World
Geode Capital Management LLC Buys 42,376 Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals stock rated buy by Roth/MKM, backed by Phase 3 results - Investing.com Nigeria
Roth Mkm Begins Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Buy at Maxim Group - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to “Strong-Buy” at Roth Capital - Defense World
Maxim Group raises Reviva stock to Buy, sets new target By Investing.com - Investing.com Australia
Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Target Price at $11.25 - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Roth Capital - MarketBeat
Maxim Group Upgrades Reviva Pharmaceuticals (NASDAQ:RVPH) to Buy - MarketBeat
Roth MKM Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Buy Recommendation - MSN
Maxim Group raises Reviva stock to Buy, sets new target - Investing.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Coverage Initiated at Roth Mkm - MarketBeat
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit - Marketscreener.com
Reviva Pharmaceuticals CEO to Present at Lytham Partners Healthcare Summit 2025 - StockTitan
Reviva Pharmaceuticals to Participate in the UBS Global Healthcare Conference - Marketscreener.com
What is Zacks Small Cap’s Estimate for RVPH FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for RVPH Issued By Zacks Small Cap - MarketBeat
RVPH: Preliminary OLE Readout - Yahoo Finance
Reviva Pharmaceuticals Strengthens Financial Position with Offering - Yahoo Finance
Reviva Pharmaceuticals Announces Positive Preliminary Data from RECOVER Trial – - Defense World
Reviva announces pricing of $18M public offering of common stock and warrants - MSN
Reviva Pharmaceuticals Shares Slide Premarket After Stock Offering - MarketWatch
CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline
Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket - Benzinga
Reviva Pharmaceuticals Announces $18M Public Offering with Warrant Package to Fund R&D Pipeline - StockTitan
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants - GlobeNewswire
Reviva Announces Proposed Public Offering - The Manila Times
Reviva Pharmaceuticals Launches Public Offering to Fund CNS Drug Development Pipeline - StockTitan
Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results - TipRanks
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia - The Manila Times
Reviva Announces Positive Preliminary Topline Data for the - GlobeNewswire
Reviva's Brilaroxazine Shows Promising Long-Term Results in Phase 3 Schizophrenia Trial - StockTitan
Reviva Pharmaceuticals Holdings, Inc. Holds Annual Meeting and Approves Increase in Authorized Shares - Defense World
Largest borrow rate increases among liquid names - TipRanks
Reviva Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low - Seeking Alpha
Analyzing Reviva Pharmaceuticals (NASDAQ:RVPH) and Akebia Therapeutics (NASDAQ:AKBA) - Defense World
RVPH: Year-End OLE Update - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Reviva Pharmaceuticals Holdings Inc - GuruFocus.com
Schonfeld Strategic Advisors LLC Increases Stake in Reviva Pharm - GuruFocus.com
Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW) Quarterly 10-Q Report - Quartzy
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):